Pharmaceutical

Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline

Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is eligible for an additional $300m in future payments.

Aug 14, 2023 - 20:00
Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline
Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is eligible for an additional $300m in future payments.
Read the original article

Tags:

Previous Article

Valneva pushes FDA approval date for chikungunya vaccine

Next Article

How the pharma industry can benefit from using modular real-time technology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca’s durvalumab recommended for bile duct cancers

AstraZeneca’s durvalumab recommended for bile duct cancers

Dec 2, 2023

Streamlining healthcare with AI for drug development

Streamlining healthcare with AI for drug development

Jun 15, 2023

STAT+: Microsoft to embed AI tool for clinical documentation in Epic’s health records software

STAT+: Microsoft to embed AI tool for clinical document...

Jan 18, 2024